Track topics on Twitter Track topics that are important to you
RTH258 for wet age-related macular degeneration met its primary and key secondary endpoints in two phase 3 studies, according to a Novartis press release.The HAWK and HARRIER trials studied the non-inferiority of RTH258 (brolucizumab, 6 mg) vs. Eylea (aflibercept, Regeneron) in regards to change in best corrected visual acuity from baseline to week 48 and average mean change between week 36 and week 48. These endpoints were met with significant P values.
Original Article: Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trialsNEXT ARTICLE
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...